Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination is a botanical formulation used primarily as a dietary supplement for the management of joint pain and inflammatory conditions such as osteoarthritis. The formulation leverages the synergistic effects of three distinct plant extracts. **Boswellia serrata extract**, particularly when standardized to 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), is a potent inhibitor of **5-lipoxygenase (5-LOX)**, thereby reducing the production of pro-inflammatory leukotrienes. **Phellodendron bark extract** (Phellodendron amurense), often provided as the branded ingredient **Nexrutine**, contains alkaloids like berberine that inhibit **cyclooxygenase-2 (COX-2)** and the **NF-kappaB** signaling pathway. **Celery seed extract** (Apium graveolens) contributes phthalides (such as 3-n-butylphthalide) which have demonstrated anti-inflammatory properties and the ability to inhibit **xanthine oxidase**, potentially aiding in the management of uric acid levels. This combination is typically administered orally to support joint mobility and reduce systemic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celery seed extract + boswellia serrata extract + phellodendron bark extract.